Since the pandemic began, biomedical companies have been sprinting to create a vaccine to protect against COVID-19. Founded in Lansing, Emergent BioSolutions is no exception.
“One of the best parts of working at Emergent is the feeling of pride — almost patriotism — that we all have for our mission,” said Adam Havey, executive vice president of business operations at Emergent BioSolutions. “It has truly been a defining moment for Emergent to be involved in creating vaccine candidates for COVID-19.”
Though the Lansing location isn’t manufacturing a COVID-19 vaccine candidate, the company is involved in several vaccine creation efforts at its facilities across the United States. Those include contract and development and manufacturing partnerships with AstraZeneca, and Johnson & Johnson. In addition, Emergent is working on a plasma-based therapy intended to treat COVID-19 in high-risk patients and those who have a high risk of exposure to the virus.
“This pandemic has created unprecedented collaboration between industry and government agencies,” said Havey.
Before the spread of COVID, Emergent was known for its work to combat health threats, including infectious diseases such as Ebola and influenza, and protections against chemical and biological agents, according to Havey. To that end, the Lansing facility manufactures anthrax vaccines. It’s all part of decades of work that has led up to this moment, Havey said.
“Our experience built up our development and manufacturing muscle that is now being used to fight the COVID-19 pandemic,” he said.